| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 3 Sep 2026 | 31 Aug 2026 |
| Titan Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/09/2026 inter alia to consider and approve 1. the proposal of bonus issue subject to requisite approvals 2. Finalize time date and venue to convene the 34th Annual General Meeting of the Company; 3.Approve the draft Notice of AGM and draft Directors Report along with annexure for the year ended March 31 2026;4. Finalize the dates of Book Closure Record Rate/ Cut-off Date and E- voting related matter for the purpose of forthcoming 34th Annual General Meeting of the company; 5.To consider and transact any other business if any which may be placed before the Board with the permission of the Chairman. Recommended Issuance of Bonus Shares, subject to shareholders approval and any other applicable regulatory and statutory approval, in ratio of 1:4 i.e. 1(one) new fully paid up Equity Shares of Rs. 2/- each for every 4 (Four) existing fully paid up Equity Shares of Rs. 2/- each held by eligible shareholders as on Record Date, which will be announce in due course. (As Per BSE Announcement Dated on: 03/09/2026) | ||
| Board Meeting | 13 Aug 2026 | 5 Aug 2026 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30 2026 Unaudited Financial Results along with the limited review report from the statutory Auditor of the Company for the quarter ended June 2026 (As Per BSE Announcement Dated on: 13/08/2026) | ||
| Board Meeting | 30 May 2026 | 20 May 2026 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the audited financial results (standalone and consolidated) and to recommend dividend if any. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. Saturday 30th May, 2026, Approval of Audited Financial Results For The Fourth Quarter And Year Ended 31st March, 2026, Recommendation of Dividend, re appointment of Cost Auditor, and Appointment of Scrutinizer (As Per BSE Announcement Dated on : 30.05.2026) | ||
| Board Meeting | 12 Feb 2026 | 3 Feb 2026 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve the unaudited standalone & consolidated financial results for the third quarter and nine months ended December 31 2025. Outcome of the board meeting held on 12th February, 2026. (As per BSE Announcement dated on: 12.02.2026) | ||
| Board Meeting | 29 Nov 2025 | 25 Nov 2025 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/11/2025 inter alia to consider and approve the proposal for alteration in the share capital by sub-division / split of existing equity shares of the Company. Outcome of Board Meeting pertaining to Sub-Division/Split of Equity Shares of Company. Intimation for alteration in Memorandum of Association (MOA) of Company (As Per BSE Announcement Dated on 29.11.2025) | ||
| Board Meeting | 11 Nov 2025 | 4 Nov 2025 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve the unaudited standalone & consolidated financial results for the second quarter & half year ended September 30 2025 Please find attached Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2025 (As Per Bse Announcement dated on 11/11/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
